Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

21.58 +0.07 (+0.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,964,594
Open 21.50
Bid (Size) 21.32 (2)
Ask (Size) 22.19 (1)
Prev. Close 21.51
Today's Range 21.46 - 21.80
52wk Range 14.87 - 22.80
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy. 
Via InvestorPlace
Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy
Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule... 
Via Talk Markets

Performance

YTD
+32.39%
+32.39%
1 Month
+0.47%
+0.47%
3 Month
+8.55%
+8.55%
6 Month
+17.73%
+17.73%
1 Year
+30.79%
+30.79%

More News

Read More
4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
2 Top Biotech Stocks Defying the Bear Market
Via The Motley Fool
The Latest Analyst Ratings for Exelixis
Via Benzinga
Where Exelixis Stands With Analysts
Via Benzinga
Analyst Expectations for Exelixis's Future
Via Benzinga
Exelixis (EXEL) Q2 2023 Earnings Call Transcript
Via The Motley Fool
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
From Exelixis
Via Business Wire
The Top Healthcare Stocks to Buy With $100
Via The Motley Fool
Exelixis Inc. (NASDAQ: EXEL) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest
Via Benzinga
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
2 No-Brainer Biotech Stocks to Buy Right Now
Via The Motley Fool
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
From Exelixis, Inc.
Via Business Wire
These Are the ONLY 3 Biotech Stocks to Consider in August 2023
Via InvestorPlace
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
Via Benzinga
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
From Exelixis, Inc.
Via Business Wire
3 Strong Biotech Performers To Watch As Sector Nears Breakout
Via MarketBeat
Topics ETFs
Exelixis Stock Sees Rising Relative Strength Rating
Via Investor's Business Daily
3 Biotech Stocks You’ll Regret Not Buying Soon
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.